U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
(NYSE: TAK) Delayed: 15.84 +0.37 (2.39%)
Previous Close $15.47    52 Week High $0.55 
Open $15.65    52 Week Low $0.55 
Day High $15.85    P/E N/A 
Day Low $15.50    EPS $-0.20 
Volume 3,126,624